1. Home
  2. SOBR vs OGEN Comparison

SOBR vs OGEN Comparison

Compare SOBR & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOBR Safe Inc.

SOBR

SOBR Safe Inc.

HOLD

Current Price

$1.11

Market Cap

3.3M

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.58

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOBR
OGEN
Founded
2004
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
2.7M
IPO Year
2008
2010

Fundamental Metrics

Financial Performance
Metric
SOBR
OGEN
Price
$1.11
$0.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
16.7M
43.7K
Earning Date
04-10-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
103.55
N/A
EPS
N/A
N/A
Revenue
$437,421.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
105.62
N/A
52 Week Low
$0.48
$0.11
52 Week High
$5.27
$9.16

Technical Indicators

Market Signals
Indicator
SOBR
OGEN
Relative Strength Index (RSI) 48.94 47.42
Support Level $0.57 $0.56
Resistance Level $2.25 $0.66
Average True Range (ATR) 0.33 0.04
MACD -0.05 0.00
Stochastic Oscillator 2.79 43.28

Price Performance

Historical Comparison
SOBR
OGEN

About SOBR SOBR Safe Inc.

Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: